» Clinical Development » Drug repositioning

We are supporting research centres and drug development companies to analyse and identify new indications for already existing compounds from a rational and highly predictive perspective. This systematic approach allows us to find the best drugs for treating any pathological condition, in either a drug- or a disease-focused mode.

Biotechnological and pharmaceutical companies need to maximize the value of their pipeline, and one of the most cost-effective strategies is to identify new indications for drugs already in the market or in the later stages of clinical development. Even if they are not effective enough for the intended initial indication, these compounds have proven to be safe and, consequently, have to undergo much less regulatory scrutiny.

Drug repositioning can no longer rely on serendipity, but has to be a directed, rational and optimized process. Sticking close to this philosophy, Anaxomics’ TPMS proprietary technology explores the full potential of systems biology analysis in order to identify new indications for already existing drugs. By navigating through the pathophysiological maps of diseases, we can discover valuable targets and identify compounds that modulate them (TPMS).

The combination of System Biology and drug repositioning is especially useful to identify new treatment for orphan and complex diseases


Drug repositioning helps you make the most of your investment

As the drug development costs keep escalating, companies are becoming increasingly interested in drug repositioning as a means to capitalize on the value of their discoveries. These are only a few of the advantages that repositioning can yield:

  • Reduced development costs and time
  • Longer life cycle and improved return on investment
  • Possibility to rescue previously failed compounds
  • Possibility to extend patent life and rescue out-of-patent compounds

From the disease to the drug or from the drug to the disease: choose the approach that better suit your needs

The systems biology in TPMS allows us to offer two different approaches to drug repurposing, depending on the specific demands of the client:


1) Drug-oriented repositioning

We offer research institutions and biopharma companies a quick and systematic analysis of their pipeline, in a flexible model that may consist of a fee-for-service approach, or a shared-risk approach. These are only a few of the services we provide in this cathegory:

  • Understanding the full indications potential of a newly characterized target
  • Identification of new uses for individual drugs or combinations from your library
  • Early exploring of the full range of potential indications in candidates undergoing clinical trials
  • Identification of new uses for commercial drugs already in the market

Download our electronic brochure about drug-oriented repositioning.


2) Disease-oriented repositioning

This strategy puts the focus on a pathological condition and attempts to identify existing drugs or combinations of drugs to treat the disease of interest.

Download our electronic brochure about disease-oriented repositioning.

drug-repositioning-2

Anaxomics has already identified individual compounds and combinations useful for treatment of Alzheimer Disease and Amyotrophic Lateral Sclerosis.


A successful example: Alzheimer's disease

alzheimer-disease